Antisense DNA and RNA agents against picornaviruses

Travis Lim, Jane Yuan, Huifang Mary Zhang, Alhousseynou Sall, Zhen Liu, Yue Su, Decheng Yang

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Anti-picornaviral antisense agents are part of a broader group of nucleic acid-based molecules developed for sequence-specific inhibition of translation and/or transcription of the target sequence through induced nuclease activity or physical hindrance. Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA). These antisense DNA and RNA molecules have been widely studied for gene functional studies and therapeutic purposes. In this review, we focus on drug development using ASO and siRNA strategies to inhibit picornavirus infections. The picornavirus genome organization and life cycle is described, followed by discussion of design considerations, chemical modifications and drug delivery approaches. Recent studies using antisense against picornavirus are reviewed. Finally, we compare the advantages and disadvantages of the antisense agents with those of other therapeutics, taking into consideration their limitations which need to be overcome to achieve the final goal of clinical application.

Original languageEnglish (US)
Pages (from-to)4707-4725
Number of pages19
JournalFrontiers in Bioscience
Volume13
Issue number12
DOIs
StatePublished - May 6 2008

Fingerprint

Antisense DNA
Picornaviridae
Antisense RNA
Nucleic Acids
Small Interfering RNA
Antisense Oligonucleotides
Genes
Molecules
Picornaviridae Infections
Catalytic DNA
Catalytic RNA
Double-Stranded RNA
Chemical modification
Gene Silencing
Transcription
Life Cycle Stages
MicroRNAs
Drug delivery
Pharmaceutical Preparations
Life cycle

Keywords

  • Antisense
  • Antisense oligonucleotides
  • Antiviral drag therapy
  • Coxsackievirus B3
  • Enterovirus
  • Phosphorodiamidate morpholino oligomer
  • Picornavirus
  • Review
  • Small interfering RNA

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Lim, T., Yuan, J., Zhang, H. M., Sall, A., Liu, Z., Su, Y., & Yang, D. (2008). Antisense DNA and RNA agents against picornaviruses. Frontiers in Bioscience, 13(12), 4707-4725. https://doi.org/10.2741/3034

Antisense DNA and RNA agents against picornaviruses. / Lim, Travis; Yuan, Jane; Zhang, Huifang Mary; Sall, Alhousseynou; Liu, Zhen; Su, Yue; Yang, Decheng.

In: Frontiers in Bioscience, Vol. 13, No. 12, 06.05.2008, p. 4707-4725.

Research output: Contribution to journalReview article

Lim, T, Yuan, J, Zhang, HM, Sall, A, Liu, Z, Su, Y & Yang, D 2008, 'Antisense DNA and RNA agents against picornaviruses', Frontiers in Bioscience, vol. 13, no. 12, pp. 4707-4725. https://doi.org/10.2741/3034
Lim T, Yuan J, Zhang HM, Sall A, Liu Z, Su Y et al. Antisense DNA and RNA agents against picornaviruses. Frontiers in Bioscience. 2008 May 6;13(12):4707-4725. https://doi.org/10.2741/3034
Lim, Travis ; Yuan, Jane ; Zhang, Huifang Mary ; Sall, Alhousseynou ; Liu, Zhen ; Su, Yue ; Yang, Decheng. / Antisense DNA and RNA agents against picornaviruses. In: Frontiers in Bioscience. 2008 ; Vol. 13, No. 12. pp. 4707-4725.
@article{22b1bd4b6dfa494fa72e4dad3cf9b8bd,
title = "Antisense DNA and RNA agents against picornaviruses",
abstract = "Anti-picornaviral antisense agents are part of a broader group of nucleic acid-based molecules developed for sequence-specific inhibition of translation and/or transcription of the target sequence through induced nuclease activity or physical hindrance. Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA). These antisense DNA and RNA molecules have been widely studied for gene functional studies and therapeutic purposes. In this review, we focus on drug development using ASO and siRNA strategies to inhibit picornavirus infections. The picornavirus genome organization and life cycle is described, followed by discussion of design considerations, chemical modifications and drug delivery approaches. Recent studies using antisense against picornavirus are reviewed. Finally, we compare the advantages and disadvantages of the antisense agents with those of other therapeutics, taking into consideration their limitations which need to be overcome to achieve the final goal of clinical application.",
keywords = "Antisense, Antisense oligonucleotides, Antiviral drag therapy, Coxsackievirus B3, Enterovirus, Phosphorodiamidate morpholino oligomer, Picornavirus, Review, Small interfering RNA",
author = "Travis Lim and Jane Yuan and Zhang, {Huifang Mary} and Alhousseynou Sall and Zhen Liu and Yue Su and Decheng Yang",
year = "2008",
month = "5",
day = "6",
doi = "10.2741/3034",
language = "English (US)",
volume = "13",
pages = "4707--4725",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "12",

}

TY - JOUR

T1 - Antisense DNA and RNA agents against picornaviruses

AU - Lim, Travis

AU - Yuan, Jane

AU - Zhang, Huifang Mary

AU - Sall, Alhousseynou

AU - Liu, Zhen

AU - Su, Yue

AU - Yang, Decheng

PY - 2008/5/6

Y1 - 2008/5/6

N2 - Anti-picornaviral antisense agents are part of a broader group of nucleic acid-based molecules developed for sequence-specific inhibition of translation and/or transcription of the target sequence through induced nuclease activity or physical hindrance. Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA). These antisense DNA and RNA molecules have been widely studied for gene functional studies and therapeutic purposes. In this review, we focus on drug development using ASO and siRNA strategies to inhibit picornavirus infections. The picornavirus genome organization and life cycle is described, followed by discussion of design considerations, chemical modifications and drug delivery approaches. Recent studies using antisense against picornavirus are reviewed. Finally, we compare the advantages and disadvantages of the antisense agents with those of other therapeutics, taking into consideration their limitations which need to be overcome to achieve the final goal of clinical application.

AB - Anti-picornaviral antisense agents are part of a broader group of nucleic acid-based molecules developed for sequence-specific inhibition of translation and/or transcription of the target sequence through induced nuclease activity or physical hindrance. Three types of nucleic acid-based gene silencing molecules can be distinguished, including DNA-base antisense oligonucleotides (ASO), nucleic acid enzymes (ribozyme and DNAzyme) and double-stranded small interfering RNA (siRNA or microRNA). These antisense DNA and RNA molecules have been widely studied for gene functional studies and therapeutic purposes. In this review, we focus on drug development using ASO and siRNA strategies to inhibit picornavirus infections. The picornavirus genome organization and life cycle is described, followed by discussion of design considerations, chemical modifications and drug delivery approaches. Recent studies using antisense against picornavirus are reviewed. Finally, we compare the advantages and disadvantages of the antisense agents with those of other therapeutics, taking into consideration their limitations which need to be overcome to achieve the final goal of clinical application.

KW - Antisense

KW - Antisense oligonucleotides

KW - Antiviral drag therapy

KW - Coxsackievirus B3

KW - Enterovirus

KW - Phosphorodiamidate morpholino oligomer

KW - Picornavirus

KW - Review

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=42949157747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949157747&partnerID=8YFLogxK

U2 - 10.2741/3034

DO - 10.2741/3034

M3 - Review article

C2 - 18508540

AN - SCOPUS:42949157747

VL - 13

SP - 4707

EP - 4725

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 12

ER -